Shire Fights Latest Class Rep In ADHD Drug Antitrust Suit

Law360 (September 23, 2020, 8:06 PM EDT) -- Shire has urged a Massachusetts federal court to reject a third potential representative for a class of direct purchasers suing over the alleged delay of a generic version of the ADHD drug Intuniv, contending the latest candidate still misses the mark.

Shire filed an opposition Tuesday to a bid from the purchasers to appoint Midwest pharmacy chain Meijer Inc. as a class representative, following the July disqualification of bankrupt wholesaler Rochester Drug Co-Operative from the role.

The opposition pointed to a motion from Shire seeking to push Meijer's claims into arbitration and said it shows the pharmacy cannot represent the class...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!